On July 29, 2019 Castle Biosciences, Inc. (Nasdaq: CSTL), reported the closing of its previously announced initial public offering of 4,600,000 shares of its common stock, which includes 600,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $16.00 per share (Press release, Castle Biosciences, JUL 29, 2019, View Source [SID1234537860]). Including the option exercise, the gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, were $73.6 million.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SVB Leerink and Baird acted as joint book-running managers for the offering and as representatives of the underwriters. Canaccord Genuity and BTIG acted as co-managers for the offering.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on July 24, 2019. The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone: (800) 808‐7525, ext. 6132, or by e‐mail: [email protected]; or Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Ave., Milwaukee, WI 53202, by telephone: (800) 792-2473, or by email: [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.